Last 1,260 INR
Change Today -1.45 / -0.11%
Volume 4.6K
ARTD On Other Exchanges
Symbol
Exchange
Natl India
As of 2:47 AM 02/28/15 All times are local (Market data is delayed by at least 15 minutes).

aarti drugs ltd (ARTD) Snapshot

Open
1,258
Previous Close
1,262
Day High
1,280
Day Low
1,242
52 Week High
02/19/15 - 1,378
52 Week Low
02/28/14 - 240.15
Market Cap
15.3B
Average Volume 10 Days
14.8K
EPS TTM
17.91
Shares Outstanding
12.1M
EX-Date
02/4/15
P/E TM
70.4x
Dividend
15.50
Dividend Yield
1.23%
Current Stock Chart for AARTI DRUGS LTD (ARTD)

Related News

No related news articles were found.

aarti drugs ltd (ARTD) Related Businessweek News

No Related Businessweek News Found

aarti drugs ltd (ARTD) Details

Aarti Drugs Limited is engaged in pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti inflammatory, cardioprotectant, antidiarrhoeals/antiprotozoles, antifungals, antiarthritis/osteoporosis, antihistamine, antibiotic, antidiabetic, alzheimer’s treatment, antihypertensive, antiBPH, sedative, vitamins, traquilizar, and antipsychotic. It also provides steroids, such as hydrocortisone sodium succinate sterile and hydrocortisone acetate; pharmaceutical intermediate products comprising valsartan, capecitabine, celecoxib, raloxifene, ketoconazole, and ziprasidone; and specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, methyl nicotinate, N-methyl methane sulphonamide, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, and para toluene sulphonyl chloride. In addition, the company’s products under development comprises Telmisartan for the treatment of cardiovascular diseases; Topiramate for anticonvulsant; Aripiprazole for the treatment of antipsychotic; Acamprosate for alcoholism treatment; Hydralazine HCl and Labetalol for the treatment of antihypertensive; Propafenone HCl for antiarrhythmic treatment; and Ticonazole for use as an antifungal. It also exports its products to 97 countries, as well as offers contract manufacturing services. Aarti Drugs Limited was founded in 1984 and is based in Mumbai, India.

Founded in 1984

aarti drugs ltd (ARTD) Top Compensated Officers

Chairman, Chief Executive Officer, Managing D...
Total Annual Compensation: 5.8M
Joint Managing Director, Executive Director, ...
Total Annual Compensation: 5.0M
Managing Director, Whole-Time Director, Membe...
Total Annual Compensation: 4.9M
Whole-Time Director, Member of Share Transfer...
Total Annual Compensation: 5.0M
Whole-Time Director
Total Annual Compensation: 484.1K
Compensation as of Fiscal Year 2014.

aarti drugs ltd (ARTD) Key Developments

Aarti Drugs Limited Proposes to Amend Articles of Association and Memorandum of Association

Aarti Drugs Limited proposed to adopt new Articles of Association of the company containing regulations in conformity with The Companies Act, 2013 and alter the capital clause of the Memorandum of Association by way of postal ballot.

Aarti Drugs Limited Announces Board Appointments

Aarti Drugs Limited announced that the board of directors at the meeting held on January 30, 2015 approved the appointment of CA Navin C. Shah and CA Priti P. Savla as independent directors up to March 31, 2019.

Aarti Drugs Limited Announces Unaudited Financial Results for the Third Quarter and Nine Months Ended December 31, 2014

Aarti Drugs Limited announced unaudited financial results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported profit from operations before other income, finance costs & exceptional items of INR 361 million against INR 304.5 million for the same period of last year. Profit from ordinary activities before tax was INR 268.6 million against INR 212.1 million for the same period of last year. Net profit for the period was INR 227.5 million or INR 18.79 per basic and diluted share against INR 141.6 million or INR 11.69 per basic and diluted share for the same period of last year. Net sales/income from operations were INR 2,596 million against INR 2,218 million for the same period of last year. For the nine months, the company reported profit from operations before other income, finance costs & exceptional items of INR 1,035 million against INR 831 million for the same period of last year. Profit from ordinary activities before tax was INR 750 million against INR 588 million for the same period of last year. Net profit for the period was INR 587.4 million or INR 48.51 per basic and diluted share against 397.6 million or INR 32.83 per basic and diluted share for the same period of last year. Net sales/income from operations were INR 8,051 million against INR 6,881 million for the same period of last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARTD:IN 1,260.35 INR -1.45

ARTD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARTD.
View Industry Companies
 

Industry Analysis

ARTD

Industry Average

Valuation ARTD Industry Range
Price/Earnings 19.3x
Price/Sales 1.4x
Price/Book 5.6x
Price/Cash Flow 14.1x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AARTI DRUGS LTD, please visit www.aartidrugs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.